Claims

1. A stable pharmaceutical formulation of an α4β7 antibody, comprising 60 mg/ml of the antibody, buffer, salt and surfactant and wherein the formulation is devoid of free amino acid.

2. The antibody formulation of claim 1, wherein the salt present in the antibody formulation controls rate of fragmentation of the antibody molecule in the formulation and also controls the rate of conversion of main peak content to basic variants at a concentration from 10 mM to less than about 100 mM.

3. A stable α4β7 antibody formulation comprising 60 mg/ml of the antibody, buffer, salt, surfactant, sugar and wherein the formulation is devoid of free amino acid.

4. The α4β7 antibody formulation according to claim 3, is stable and maintains at least 97% of monomeric content of the antibody and controls the low molecular weight species to less than 1.5% in the formulation, when stored at 50 °C for two weeks.

5. The α4β7 antibody formulation according to claim 3, contains less than 15% of basic variants when stored at 50 °C for two weeks.

6. The pH of the formulation in claim 1 or claim 3, is about 6.0 to 7.0.

7. The formulation of claim 1 or 3, is a liquid or lyophilized formulation.